Using Deep Learning to Find New Therapeutic Antibodies

(startupticker.ch, August 24, 2020)

ETH Zurich spin-off deepCDR Biologics recently won CHF150k from Venture Kick to continue their early growth and client acquisition. By combining gene editing, deep sequencing, and deep learning, the Basel-based startup has developed a novel technology platform that radically accelerates the therapeutic antibody discovery process, compared to conventional experimental screening methods. In addition, these processes are highly scalable and allow running multiple drug discovery and optimization campaigns for a fraction of the costs. Within the context of the ongoing global pandemic, deepCDR has collaborated with ETH Zurich to help discover highly potent and neutralizing antibodies for the treatment of COVID-19.